The Irish specialty pharmaceutical company will pay $3.1 billion in cash to acquire a business that makes prescription products for ulcerative colitis, osteoporosis, and overactive bladder. It also will gain drug development capabilities, a product pipeline, and manufacturing facilities in Puerto Rico and Germany.
At double the Irish firm's current size, the P&G business transforms Warner Chilcott into a global pharmaceutical company and expands its presence in women's health care, CEO Roger Boissonneault says. For the 12 months ending June 30, P&G's pharmaceutical business had revenues of about $2.3 billion and net income of $540 million. Warner Chilcott's annual sales are just less than $1 billion.
The deal allows P&G to focus on its personal care, beauty, and household product divisions. In 2006, P&G jettisoned its discovery-phase pharmaceutical R&D efforts in favor of in-licensing late-stage compounds, and in late 2008 the company said it wanted to exit the drug business outright.
In a written statement, P&G's management calls Warner Chilcott a better investor in the drug assets, brands, and capabilities because of its focus on pharmaceuticals. P&G, meanwhile, is putting its priority on its consumer health care businesses.
The majority of the 2,300 employees in P&G's pharmaceutical business are expected to move to Warner Chilcott. The welfare of these men and women, P&G CEO Bob McDonald says, "was a key consideration in the choice of a buyer."